Clarity Pharmaceuticals Signs Copper Supply Deal With US-Based Physics Firm; Shares Rise 12%

MT Newswires Live
17 Apr

Clarity Pharmaceuticals (ASX:CU6) signed a commercial supply agreement with US-based Nusano for copper-64, a key isotope used along with the company's theranostic radiopharmaceutical SAR-bisPSMA for diagnosing and treating cancer, according to a Thursday filing with the Australian bourse.

Production will start at Nusano's Utah facility this year, with copper-64 deliveries to start in early 2026, the filing said.

The agreement, effective Wednesday, runs for an initial three years with automatic two-year renewals, the filing added.

Financial terms were not disclosed.

Shares of the company rose almost 12% in recent Thursday trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10